RxDoctor Payments Data

Christopher Alvarado, DO

Internal Medicine · Lansing, MINPI 1073772968

Payments from drug & device makers

$35,388in general payments, 2019–2025

Across 608 payments — averaging $58.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$17K
  • Exact Sciences$10K
  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$985
  • Lilly USA, LLC$650
  • plus $4K from 44 others

What the payments were for

  • Speaking & faculty fees$24,31369%
  • Travel & lodging$1,3694%
  • Food & beverage$9,61127%
  • Education$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,388 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$84,558
Medicare patients
111
Services billed
1,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$79,442
EliquisApixaban60$64,138
JardianceEmpagliflozin43$56,997
JanuviaSitagliptin Phosphate43$54,208
TrulicityDulaglutide29$48,278
ForteoTeriparatide11$43,924
MounjaroTirzepatide37$40,794
KerendiaFinerenone25$35,328
Bydureon BciseExenatide Microspheres26$33,233
XareltoRivaroxaban23$31,368
FarxigaDapagliflozin Propanediol27$31,161
MyrbetriqMirabegron38$30,488
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$27,646
Repatha SyringeEvolocumab21$14,663
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$13,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Forteo, Mounjaro$650$132,99677 claims
Novo NordiskOzempic$985$79,44261 claims
PfizerEliquis$17,154$64,13860 claims
Boehringer IngelheimJardiance$366$56,99743 claims
MerckJanuvia$64$54,20843 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,085$43,75044 claims
BayerKerendia$236$35,32825 claims
Johnson & JohnsonXarelto$87$31,36823 claims
Astellas Pharma US IncMyrbetriq$69$30,48838 claims
GSKTrelegy Ellipta$253$27,64619 claims
Sanofi-aventis U.S. LLCLantus$14$1,73014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →